Research Analysts’ Weekly Ratings Changes for Zoetis (ZTS)

A number of firms have modified their ratings and price targets on shares of Zoetis (NYSE: ZTS) recently:

  • 11/29/2017 – Zoetis was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $80.00 price target on the stock.
  • 11/24/2017 – Zoetis had its “neutral” rating reaffirmed by analysts at UBS AG.
  • 11/17/2017 – Zoetis was given a new $80.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 11/10/2017 – Zoetis had its “buy” rating reaffirmed by analysts at Jefferies Group LLC.
  • 11/7/2017 – Zoetis was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/3/2017 – Zoetis had its price target raised by analysts at BMO Capital Markets from $65.00 to $70.00. They now have a “market perform” rating on the stock.
  • 11/3/2017 – Zoetis had its price target raised by analysts at Morgan Stanley from $61.00 to $70.00. They now have an “equal weight” rating on the stock.
  • 11/2/2017 – Zoetis had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $65.00 price target on the stock.
  • 11/1/2017 – Zoetis was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Growth at Zoetis is being driven by industry-leading dermatology portfolio consisting of Apoquel and Cytopoint and new oral parasiticide Simparica. Sales of companion animal products are being further boosted by further penetration of new products in key countries outside of the U.S. such as Japan, Brazil, and Canada while growth in livestock portfolio was balanced across the U.S. and international business segments. However, swine performance is being impacted by competition from Fostera. The acquisition of Nexvet Biopharma will further strengthen Zoetis’ chronic pain management franchise. Shares of Zoetis have outperformed the industry in 2017 in the last six months. However, Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco.”
  • 11/1/2017 – Zoetis was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/31/2017 – Zoetis was given a new $75.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “IDEXX Laboratories this morning provided strong 2018 organic growth forecasts of 9% to 11% driven by the strong growth in its Companion Animal Diagnostics segment.””
  • 10/26/2017 – Zoetis was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/25/2017 – Zoetis was given a new $65.00 price target on by analysts at BMO Capital Markets. They now have a “hold” rating on the stock.
  • 10/24/2017 – Zoetis had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $75.00 price target on the stock.
  • 10/24/2017 – Zoetis had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $65.00 price target on the stock.
  • 10/13/2017 – Zoetis was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/12/2017 – Zoetis was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $71.00 price target on the stock. According to Zacks, “Growth at Zoetis is being driven by industry-leading dermatology portfolio consisting of Apoquel and Cytopoint and new oral parasiticide Simparica. Sales of companion animal products are being further boosted by further penetration of new products in key countries outside of the U.S. such as Japan, Brazil, and Canada while growth in livestock portfolio was balanced across the U.S. and international business segments. However, swine performance is being impacted by competition from Fostera. The recent acquisition of Nexvet Biopharma will further strengthen Zoetis’ chronic pain management franchise. Shares of Zoetis have outperformed the industry in 2017 so far. However, Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco.”
  • 10/6/2017 – Zoetis was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Zoetis Inc. (NYSE ZTS) traded up $0.68 during trading hours on Thursday, hitting $72.29. 2,602,127 shares of the company traded hands, compared to its average volume of 2,780,326. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. The firm has a market cap of $34,787.51, a price-to-earnings ratio of 32.75, a price-to-earnings-growth ratio of 2.10 and a beta of 1.02. Zoetis Inc. has a 1-year low of $48.55 and a 1-year high of $72.71.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.02. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.52 EPS. equities research analysts forecast that Zoetis Inc. will post 2.37 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be issued a $0.105 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.58%. Zoetis’s dividend payout ratio is currently 22.11%.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply